Quantitative Cell-Based Reporter Gene Bioassays to Advance Individual or Combination Cancer Immunotherapy
Part # PS360
Jamison Grailer, Jun Wang, Julia Gilden, Pete Stecha, Denise Garvin, Michael Beck, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711
A major challenge in the development of antibody-based biologics drugs is access to quantitative and reproducible functional bioassays. In contrast to the cumbersome, variable methods currently used that rely on primary cells, we have developed a portfolio of functional cell-based reporter bioassays to easily measure the activity of biologics drugs designed to target immune checkpoint receptors including co-inhibitory (e.g. PD-1, CTLA-4, LAG-3) and co-stimulatory (e.g. 4-1BB, GITR, OX40) receptors. These bioassays consist of stable cell lines that express luciferase under the precise control of receptor-mediated intracellular signals. Here we describe the application of these MOA-based bioassays for biologics drug discovery, development, potency and stability studies.
Printed in USA.